Second-line drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis isolates in Aegean Region - Turkey

Özkütük N., Sürücüoǧlu S., Gazi H., Coşkun M., Özkütük A., Özbakkaloǧlu B.

Turkish Journal of Medical Sciences, vol.38, no.3, pp.245-250, 2008 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 3
  • Publication Date: 2008
  • Journal Name: Turkish Journal of Medical Sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.245-250
  • Keywords: Extensively drug-resistant tuberculosis (XDR-TB), Multidrug-resistant tuberculosis (MDR-TB), Mycobacterium tuberculosis, Second-line drugs, Susceptibility tests
  • Dokuz Eylül University Affiliated: Yes


Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard shortcourse regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 μg/ml, 1.25 μg/ml, 5.0 μg/ml, 1.0 μg/ml, 0.5 μg/ml, and 2.0 μg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region. © TÜBİTAK.